Safe Compounding Act

We represent many thousands strong that supports safe pharmaceutical compounding. We represent pharmacists, doctors, veterinarians, and most importantly patients that are passionate about protecting prescription health choices for the chronically ill and terminal patients (both humans and pets) who need compounded medication. Currently these medications are under attack by the FDA through the lobbying efforts of Big Pharma, creating a conflict of interest. The FDA is trying to remove lifesaving patient options under the auspice of safety and limit the doctor's ability to provide lifesaving and cost-effective medications via 503A pharmaceutical compounding.

If a prescription is written by a licensed healthcare provider for a chronically ill or terminal patient, it should be filled and administered to the patient. Many of these medications have been in use for years and FDA is working to remove them.

Why We Are Engaged

Big Pharma Spent Nearly $50 Million On Lobbying (to influence pharmacy laws) In Just The Opening Months Of 2020 Alone To Maintain Their Control Over The Prescription Landscape Through Donating To Politicians And Lawmakers On Both Sides Of The Aisle Thereby Creating "Nominating Guidance" To The FDA.

Our mission is to fight for fellow American's freedoms that are being removed and challenged by the FDA via the lobbying powers of Big Pharma. We aim to fight for and defend patient and doctor prescription freedom rights to help save and protect human and pet lives.

FDA & Big Pharma Abuses

Industry-leading pharmaceutical companies, often referred to collectively as “Big Pharma,” remain one of the public’s least trusted entities. A major reason for this lack of trust is drug producers' perceived influence over powerful legislative and regulatory bodies.

David Mitch, president and founder of the campaign group, Patients for Affordable Drugs, echoed this sentiment when he wrote, “I sort of view Big Pharma, as an industry, as an octopus with many tentacles, and at the end of every tentacle is a wad of cash… It reaches into academic medical centers, professional organizations, patient organizations, state houses, campaigns, Congress – they’re everywhere.”

A recent career change from one of the most powerful men in the industry isn’t helping this image.

After serving as Commissioner for the Food and Drug Administration for just under two years, Scott Gottlieb unexpectedly resigned in April to spend more time with his family. He left behind a legacy of unprecedented expansion of the FDA’s regulatory powers, a persistent commitment towards approving generic drugs, and an unclear path for the future of the agency.

Eighty-three days later, Gottlieb announced he was joining Pfizer’s advisory board. He will also serve on the company’s science and technology committee as well as its regulatory and compliance committee. This is a conflict of interest, and this type of conflict is not uncommon.

Source: https://www.fdareview.org/2019/07/29/worried-about-big-pharma-then-reduce-the-fdas-regulatory-power/